Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: A significant number of patients with chronic lymphocytic leukemia (CLL) have an increased risk of bleeding. This risk is further increased when taking ibrutinib, a new effective therapy for CLL. Platelets are the key player in haemostasis and thrombosis. In this study, we first char...

Descripción completa

Detalles Bibliográficos
Autores principales: Elaskalani, Omar, Gilmore, Grace, Hagger, Madison, Baker, Ross I., Metharom, Pat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741389/
https://www.ncbi.nlm.nih.gov/pubmed/36497231
http://dx.doi.org/10.3390/cancers14235750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741389/
https://www.ncbi.nlm.nih.gov/pubmed/36497231
http://dx.doi.org/10.3390/cancers14235750

Ejemplares similares